Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.

Among older adults with diabetes, empagliflozin was associated with a lower number of inpatient days, hospitalizations, ED visits, and office visits and with lower costs of care compared with DPP-4is, especially in those with history of CVD.